AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$RXRX

HERSHBERG ROBERT sold $125K of RXRX

HERSHBERG ROBERT sold 25,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $5.00 ($0.12M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Oct 7, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Bearish
medium confidence
Mentioned
$RXRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

While the sale is small, it provides transparency and may cause short‑term price adjustments.

02

Market read

A modest insider sale with limited trading relevance; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential upcoming clinical data releases or partnership news could outweigh the impact of this modest insider sale.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales, often used for routine portfolio rebalancing.

Company-level read

Ticker impact

$RXRXBearishMedium confidence
Context

Director Robert Hershberg sold 25,000 shares for $125,000 via a 10b5-1 plan, reducing his stake to 162,156 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A small $125K sale by a director is disclosed via Form 4; while the amount is modest, it signals potential concern and can prompt short-term price dip.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine and unlikely to shift sector sentiment.

Regional

No regional effect; the filing pertains to a US‑listed company only.

Global

Limited global relevance; the transaction size is too small to affect broader markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • Company
    Recursion Pharmaceuticals, Inc.

    US biotech listed on NASDAQ under ticker RXRX.

  • Individual
    Robert Hershberg

    Director of Recursion Pharmaceuticals who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype

Recursion Pharmaceuticals (RXRX) stock rose 4.26% on optimism over AI-driven drug advances. The company reported positive Phase 1b/2 trial results for REC-4881 and early Phase 1 data for REC-1245. Sanofi optioned a candidate, triggering a $10M milestone. RXRX raised $200M, extending its cash runway. The stock has high volatility, trading at a 43x P/S ratio with negative margins.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Ignite Momentum

Recursion Pharmaceuticals (RXRX) stock rose 3.85% on news of a Sanofi partnership and ARK Investment's purchases. The company reported positive clinical data for REC-4881 and REC-1245, and raised $200M in equity. RXRX has a strong cash position and a runway into 2029, but remains unprofitable with negative margins.

stockstotrade.com3 min
OCT 16
$RXRXHighAI 9/10

Key facts: RXRX REC-4881 strong efficacy, clean safety; Runway into 2029

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

tradingview.com1 min
OCT 15
$RXRXMed

Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

Recursion Pharmaceuticals (RXRX) shares surged 17.9% after Sanofi initiated development of drug molecules, triggering a $10M milestone payment, totaling $144M received. RXRX may earn over $300M more in milestones and royalties if approved. The collaboration, started in 2022, focuses on AI-enabled small molecule therapies in immunology and oncology. Hedge fund holdings in RXRX increased 16% QoQ to $287.9M, despite a drop in the number of funds invested.

insidermonkey.com2 min